Cloud Pharmaceuticals' Don Van Dyke On Applying Cloud Computing To Drug Discovery
Executive Summary
Biotech uses cloud computing and artificial intelligence to accelerate the discovery and design of small-molecule drug candidates across a broad range of therapeutic areas.
Boston – Cloud Pharmaceuticals Inc. Chief Operating Officer Don Van Dyke spoke with Scrip at BioPharm America 2016 about how the company uses cloud computing to accelerate the discovery and design of novel small-molecule drug candidates in therapeutic areas such as cancer, inflammatory disease, infectious disease and central nervous system disorders.
Van Dyke discussed how an ongoing partnership helped Cloud develop its technology for creating drug candidates that can pervade the blood-brain barrier and the company's virtual model, in which it performs the computational chemistry and partners out bench preclinical processes.
BioPharm America 2016: Interview with Don Van Dyke
Cloud COO Don Van Dyke
EBD Group, Informa Pharma Intelligence